Docetaxel (Taxotere®) is recommended for restricted use within NHS Wales in combination with cisplatin and 5-fluorouracil (5-FU) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Docetaxel (Taxotere®) should be restricted for use as an induction treatment for patients of good performance status (0 or 1) anticipated to be receiving chemo-radiotherapy. Docetaxel (Taxotere®) is not suitable for shared care within NHS Wales.